|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
IMMUNOBIOLOGY
From Unité INSERM 445, Institut Cochin de
Génétique Moléculaire; Laboratoire d'Immunologie
Cellulaire et Tissulaire, Hôpital de la
Pitié-Salpêtrière; Unité de
Rétrovirologie Moléculaire, Institut Pasteur; Service
d'Immuno-Hématologie, Hôpital St Louis; and Service
d'Immunologie Clinique, Hôpital Européen Georges Pompidou;
all of Paris, France.
Human immunodeficiency virus (HIV) infection is characterized by
the massive infiltration of secondary lymphoid organs with activated
CD8+ T lymphocytes. While converging data indicated that
these cells were HIV-specific cytotoxic T lymphocytes (CTLs)
responsible for HIV spread limitation, direct evidence was lacking.
Here, the presence of HIV-specific effector CTLs was demonstrated
directly ex vivo in 15 of 24 microdissected splenic white pulps from an untreated patient and in 1 of 24 tonsil germinal centers from a second
patient with incomplete viral suppression following bitherapy. These
patients had plasma HIV RNA loads of 5900 and 820 copies per
milliliter. The frequencies of HIV-1 DNA+ cells in
their lymphoid organs were more than 1 in 50 and 1 in 175, respectively. Spliced viral messenger RNA (a marker for ongoing viral
replication) was present in most immunocompetent structures tested.
Conversely, CTL activity was not found in spleens from 2 patients under
highly active antiretroviral therapy, with undetectable plasma viral
load. These patients had much lower spleen DNA+ cell
frequencies (1 in 2700 and 1 in 3800) and no white pulps containing
spliced RNA. CTL effector activity as well as spliced viral messenger
RNA were both concentrated in the white pulps and germinal centers.
This colocalization indicates that viral replication in immunocompetent
structures of secondary lymphoid organs triggers anti-HIV effector CTLs
to these particular locations, providing clues to target therapeutic intervention.
(Blood. 2001;97:2695-2701) During the chronic phase of infection, antigenic
stimulation drives human immunodeficiency virus (HIV) replication in
vivo.1,2 Accordingly, HIV replication is mainly restricted
to secondary lymphoid organs, which are the major sites of primary and
secondary immune responses.3-11 Lymph nodes and tonsils
have an organized structure with primary follicles, germinal centers
(or secondary follicles) generated in response to antigens, surrounded
by T-cell areas. The spleen is the major secondary lymphoid organ for
the defense against bloodborne pathogens. It is divided into red pulp and white pulps. The latter comprises periarteriolar lymphoid sheaths Sequencing of HIV from individual white pulps suggested bursts of local
viral replication, but analysis of the viral quasi species showed that
viral replication was strongly restricted.16-19b The best candidates to limit viral spread are the HIV-specific CD8+ cytotoxic T lymphocytes (CTLs). Indeed, these cells
are found in large numbers in clinical samples from infected
patients18,20 and inhibit HIV replication in
vitro21 by different mechanisms: direct lysis of infected
cells or inhibition of viral replication by interleukin or chemokine
secretion.22 After peaking at high levels during primary
infection, the viral load decreases at a time when CTL responses are
high, while HIV-specific antibodies are usually
undetectable.23-26 The viral load then reaches a set point, which is predictive of the clinical outcome.27 In
this context, some CTL responses were correlated with decreased viral loads and with a better prognosis.27-30 More recently,
CD8+ T-cell depletion in simian immunodefiency virus
(SIV)-infected macaques was shown to lead to an immediate rise
of the viral load, further confirming the role of CD8+ T
lymphocytes in limiting disease progression.31-33
At the site of HIV replication, ie, lymphoid organs, massive
infiltration of clonally expanded CD8+ T cells is
observed.17,34,35 These lymphocytes contain
TiA1+ granules, indicating their cytotoxic effector
potential, and have a memory phenotype, especially in the germinal
centers.35 Individual white pulps from HIV patients were
found to have a discrete distribution of T-cell clones characterized by
their rearranged T-cell receptor Clinical specimens
Chromium release test
Flow cytometry Flow cytometric analysis of surface markers was done on cell suspensions. Immunostaining was performed using anti-CD3 (SK7) peridinin chlorophyll protein, anti-CD4 (SK3) fluorescein isothiocynate (FITC), anti-CD8 (Leu-2a) phycoerythrin (PE), anti-CD25 (2A3) FITC, anti-CD38 (HB7) PE, anti-HLA-DR (L243) FITC (Becton Dickinson, Pont-de Claix, France), anti-CD19 (J4119) PC5, anti-CD45RA (ALB11) FITC, anti-CD45RO (UCHL1) FITC, and TiA1 (2G9) PE (Immunotech, Marseille, France), according to the manufacturer's instructions. For intracellular TiA1 staining, the cells were washed in PBS-bovine serum albumin 0.1% saponine and incubated with TiA1 for 20 minutes. Flow cytometry was performed on a FACSCalibur instrument and analyzed with the CellQuest software (Becton Dickinson).Nucleic acid analysis Total RNA and DNA were extracted from individual white pulps or germinal centers or cell pellets using Master Pure extraction kit (Epicentre, Madison, WI). Briefly, 2 µg transfer RNA (Sigma) was added to each sample as carrier, cells were lysed in the presence of proteinase K for 15 minutes, and the cell lysate was then split to purify either RNA or DNA according to the manufacturer's procedure. On each extract, several PCR amplifications were performed to detect proviruses, full-length viral RNA, and spliced RNA. To avoid contaminations, the reverse transcriptase (RT) and PCR steps of the amplifications were performed in one tube. LV13 oligonucleotide was used as primer for complementary DNA synthesis.16 For unspliced RNA and DNA, LV13 and LV15 primers were used in the first cycle while SK122/123 16 served as nested primers. Negative controls without RT were performed. For spliced RNA amplification, LV15 primer was replaced by LTR-SD: TCTCTCGACGCAGGACTCGGCTTG. Positive controls of DNA and RNA amplification were performed using the following CD3 gene-specific primers: first cycle, for DNA, CD3A: GCCTGGCTGTCCTCATCCTGGCTATC and CD3B: TGGCCTATGCCCTTTTGGGCTGCATTC,1 for RNA, CD3OUT5: GACATGGAACAGGGGAAGGG and CD3OUT3: GAGAAAGCCAGATATGGTGG; nested cycle, for both DNA and RNA, CD3IN5: CTTCTTCAAGGTACTTTGG and CD3IN3: ACTTCTGTAATACACTTGGAGTGG. The frequency of HIV DNA-containing cells was determined by limiting-dilution nested PCR as described,13,16 using noninfected B-lymphoblastoid cells as carriers.
Phenotypic analysis of patient lymphoid organ bulk cell populations Spleens from 3 patients and tonsils from 1 patient who underwent surgery for therapeutic reasons were collected (Table 1). The different populations present in bulk mononuclear cells from these lymphoid organs were analyzed by flow cytometry. Infiltration by CD3+CD8+ cells was found in untreated (patient B) and treated (patients C and R) HIV+ patient spleens, with a concomitant decrease in the proportion of B lymphocytes compared with normal organ donors (Table 2). In these 3 patients (Table 2), conversely to others (data not shown), the proportion of CD4+ T lymphocytes was not decreased when compared with controls. Patient R had the most important CD8+ T-cell infiltration, with signs of activation (elevated CD38 expression) in a significant proportion of these cells. However, in these bulk spleen cells, none of the patients had an elevated proportion of CD25, the interleukin-2 receptor chain, a
T-cell activation marker, and the high proportion of cells
bearing TiA1, a marker of cytotoxic granules, was rather low compared
with that observed in normal spleens. In parallel, phenotypic analysis
was performed on a few microdissected splenic white pulps from patient B. About 23% to 32% of the cells from these white pulps were
CD8+, most being CD45RO+, HLA-DR+
(data not shown). Fluorescence-activated cell sorter analysis could not
be performed on microdissected structures from all of the patients, but
these data indicate that phenotypic analysis of total splenocytes does
not reflect the individual splenic white pulp populations.
Direct HIV-specific CTL effector activity in microdissected white pulps or germinal centers Hyperplastic white pulps or germinal centers were microdissected from the spleen or the tonsil of the HIV+ patients. The cells were extracted by mechanical disruption and collagenase-DNase treatment (as in "Materials and methods"). From these structures, 0.02 × 106 to 4.1 × 106 leukocytes were isolated (Table 1), which was enough to perform cytotoxicity assays. Target cells consisted of autologous or partly HLA-matched Epstein-Barr virus-transformed B-cell lines, because HLA typing of the patients was obtained before splenectomy. Due to the limited number of effector cells, CTL activity was tested on targets infected with a mixture of recombinant vaccinia viruses expressing gag, RT, or glycoprotein 160 genes of HIV-1 Lai. Control targets were infected with wild-type vaccinia virus.HIV-1-specific cytotoxic activity was detected ex vivo in most splenic
white pulps from patient B, who was not receiving antiretroviral treatment and had a plasma viral load of 5900 copies per milliliter (Figure 1 and Table 1). Fifteen of 24 white pulps showed an HIV-specific cytotoxicity at more than one
effector:target ratio (white pulps 2, 3, 6, 9-13, 17-20, 22-24, Figure
1, Table 3, and not shown). Moreover, in some of
these CTL-containing white pulps (ie, white pulps 2, 12, 18, 19, 22),
the chromium release remained significantly positive (more than 10% of
anti-HIV-specific lysis) even at an effector:target ratio of 10:1 or
less, suggesting a high frequency of anti-HIV-specific CTLs in these
structures.
Twenty-four white pulps, microdissected from the spleen of patients C
and R, were tested for CTL activity. These patients were efficiently
treated with highly active antiretroviral therapy (HAART), their plasma
viral load being under the detection limit (Table 1). No CTL activity
was found directly ex vivo from these structures (Figure
2). A direct CTL activity was also
detected in one tonsilar germinal center of 24 tested from patient K,
who was treated with zidovudine (AZT) and didanosine (ddI) only and showed incomplete viral suppression and a plasma viral load of 820 copies per milliliter. In this particular germinal center (Figure 2), a
57% specific chromium release was obtained at an effector:target ratio
of 22:1 against the HIV expressing targets, while wild-type infected
targets were not recognized. MHC class I restriction could be
demonstrated by blocking the CTL activity with anticlass I monoclonal
antibodies (data not shown).
Notably, no CTL activity was detected in bulk spleen or tonsil mononuclear cells in any of the patients (SMCs or TMCs, Figures 1 and 2). Therefore, the CTL activity found in some of the immunocompetent structures was much higher than the global CTL activity found in the lymphoid organs. These results point to a concentration of anti-HIV-specific CTLs in many splenic white pulps from the untreated patient and in one of the germinal centers analyzed from the patient under AZT and ddI treatment, while in the patients under efficient triple therapy no CTL activity was detectable in the immunocompetent structures of the spleen. Proviral DNA and HIV replication HIV nucleic acids were detected in bulk mononuclear cells either by limiting dilution or in fixed number cell extracts and were detected in cells from individual white pulps or germinal centers. PCR allows detection of HIV-1 proviral DNA, while RT-PCR shows the presence of either unspliced RNA, which mostly represents virions trapped on FDCs in the germinal centers, or spliced RNA, which detects viral transcription.HIV infiltration was analyzed by limiting-dilution
PCR13,16 on bulk lymphoid organ cells isolated from the 4 patients. As shown in Table 4, the
frequency of infected cells was 1 to 2 logs higher in the 2 patients
with a detectable plasma viral load (patients B and K, > 1:50 and
1:175, respectively) than in the 2 others (patients C and R, 1:2700 and
1:3800, respectively). When analyzed in extracts from
2 × 105 splenic or tonsillar bulk mononuclear cells,
proviral DNA and viral RNA were found in the lymphoid organs from the 4 patients irrespective of their plasma viral load; conversely, spliced
RNA was not detected, indicating low levels of replication in all 4 patients (Table 4, bulk cells).
The presence of HIV RNA (spliced and unspliced) was analyzed in the white pulps of patient B tested for anti-HIV CTL activity (most of the cells were used for the CTL assay, and the remaining cells, ie, 6% of each white pulp, were tested by PCR and RT-PCR). Genomic (unspliced) RNA was detected in all 16 samples analyzed (Table 3). Moreover, 5 of the white pulps showed evidence of ongoing viral replication, as determined by the amplification of spliced viral mRNA (ie, white pulps 4, 10, 11, 12, and 19). Of these 5 white pulps, 4 contained effector anti-HIV CTLs (Table 3 and Figure 1). Because the number of cells remaining for PCR after the CTL assay was limited, HIV-DNA was amplified from 5, 9, and 8 total white pulps from patients B, C, and R, respectively, as well as from 9 germinal centers from patient K's tonsil (Table 4). All the samples were positive except for 2 of 9 white pulps from patient C (Table 4), confirming the presence of HIV-infected cells in most of the immunocompetent structures of the secondary lymphoid organs. The same white pulps or germinal centers were also screened for the presence of viral RNA and intracellular spliced mRNA. HIV-1 RNA was found in 5 of 5 white pulps from patient B, consistent with bulk cell data. Spliced RNA was found in 4 of 5 white pulps from this patient, in contrast to the negative result obtained with bulk cells (Table 4). Similar results were obtained for patient K (2 of 2 germinal centers contained both full-length and spliced viral RNA). However, in treated patients, while all the white pulps did contain HIV infected cells, no evidence of sustained viral replication was observed (Table 4, 0 of 4 and 0 of 5 positive white pulps for spliced RNA). These data show that the frequency of cells bearing HIV proviral DNA was consistent with the level of plasma viremia. Moreover, cells containing replicating virus (spliced RNA) were found, as well as anti-HIV CTLs, concentrated in the white pulps or germinal centers of patients with detectable viremia. Patients under effective triple therapy showed neither CTL infiltration nor viral replication within their white pulps, consistent with an efficient control of viral replication.
In this report, direct evidence of the HIV-specific lytic function of the CD8+ lymphocytes infiltrating single white pulps or germinal centers from infected patients is presented for the first time. Moreover, these cells were shown to colocalize with productively HIV-infected cells in the immunocompetent structures of secondary lymphoid organs. This had been suggested, but not demonstrated, by previous data using T-cell receptor sequence analysis in splenic white pulps or in situ observation of CD8+CD45RO+TiA+ cells in lymph node germinal centers.17,35 HIV-specific memory CTLs have been found in bulk spleen cells from infected patients,36 and SIV-specific memory CTLs have recently been observed in lymph nodes from experimentally infected macaques.37 However, their localization in the white pulps or germinal centers, where most of the viral replication takes place,12,35 was not studied. In another report, HIV epitope-specific CTLs expanded in vitro and genetically modified were reinfused in patients and were shown to migrate to the lymph nodes, adjacent to productively infected cells, in the parafollicular regions.38 These regions are contained in the immunocompetent structures that were microdissected in the present work. Here, the CTL activity was concentrated in the white pulps or germinal centers, because it was below detection levels in bulk mononuclear cells isolated from the same lymphoid organs. The presence of viral DNA or RNA was analyzed at the level of individual white pulps or germinal centers. Proviral DNA was detected in the tested white pulps from patients B and R, most of those from patient C, and all germinal centers tested from patient K, in accordance with previous results obtained in spleens or lymph nodes.11,16,17,35 Unspliced RNA was found in all of the immunocompetent structures from the 2 patients with detectable plasma viral loads, while it was rarely detected in the 2 other patients. Unspliced RNA is a sign that the white pulps were, or had been, the sites of viral replication. Indeed, most viral unspliced RNA represent viral particles retained on the FDC surfaces.15 Viral particles in splenic white pulps from patients B and K seemed more widespread than in the lymph node germinal centers from asymptomatic patients studied previously by in situ hybridization, who had detectable virus in only 15% to 30% of their germinal centers.35 However, the nested RT-PCR used here is much more sensitive than in situ hybridization, because it can detect as little as one infected cell. While all the white pulps analyzed from patient B contained viral particles (Table 3), only 15 of 24 displayed HIV-specific CTL activity. The presence of HIV-producing cells was analyzed by PCR amplifying spliced viral mRNA in some of the pulps. It was detected in only 4 of 10 CTL+ white pulps. However, only a small fraction (about 6%) of each white pulp was available for PCR analysis after using cells for the CTL assay. Spliced RNA was thus analyzed in 5 total white pulps from patient B. Viral replication was detected in 4 of 5 white pulps, whereas it was undetectable in bulk lymphoid organ cells, suggesting that most of the immunocompetent structures of this spleen are the site of active viral replication despite the absence of detectable CTL activity in 9 of 24 pulps tested. This discrepancy between the detection of viral replication and CTL activity may have several explanations. First, the sensitivity of the chromium release assay is limited. Detection using MHC-peptide tetramers is more sensitive and has allowed finding SIV gag-specific CTLs in macaques and reinfused HIV-specific clones in patient secondary lymphoid organs.37,38 However, in natural HIV infection analyzed here, a dominant, highly represented CTL response directed against the single epitope presented in the tetramers may not be present at the very time of splenectomy. Lysis of target cells infected with 3 different recombinant viruses, expressing 3 widely recognized proteins, is expected to be more consistent. Moreover, T cells binding MHC-peptide tetramers can be nonfunctional.39,40 Second, the epitopes presented by the targets may be different from the variant epitopes presented by the cells of the patient. This might formally also be a possibility for the absence of effector CTL detection in the 2 HAART-treated patients, ie, mutants induced by therapy; however, 3 different whole proteins containing multiple epitopes were tested, and after stimulation in culture anti-HIV memory CTLs were detectable on the same target cells. Third, and more importantly, it is possible that some of the white pulps analyzed here contained recently developed germinal centers, where HIV replication, which mostly occurs in antigen-stimulated T cells, was identified by RT-PCR but still too weak to induce a CTL infiltration detectable using a chromium release assay.1,41 Indeed, HIV enters the immunocompetent structures of secondary lymphoid organs in the form of integrated proviral DNA in CD4+ T lymphocytes. Antigen-specific stimulation of these latently infected cells is necessary to initiate viral replication and HIV protein production.1 This in turn induces HLA class I-restricted HIV peptide presentation at the surface of infected cells, a prerequisite to local CTL infiltration and stimulation. Fourth, in immunocompetent structures analyzed totally for the presence of nucleic acid, without diverting most of the cells for a CTL assay, the presence of spliced RNA was consistent with the plasma viral load, the frequency of DNA-positive cells in the bulk cells, and the detection of CTLs directly ex vivo. The detection of HIV-specific effector CTLs ex vivo in the white pulps and germinal centers from 2 patients is consistent with the detection of viral RNA in their plasma and with that of spliced RNA (replicating virus) in most of the immunocompetent structures of their secondary lymphoid organs. These patients were not treated by HAART at the time of surgery. Conversely, the 2 patients who had no detectable CTLs in their lymphoid organs had undetectable plasma viral loads as a result of HAART. Viral RNA (ie, viral particles) and proviral DNA were still detectable in their lymphoid organs, as reported for other patients42,43; however, if viral RNA was present in bulk SMCs, no evidence of viral replication was observed in the microdissected white pulps from these patients. It has been shown that several months after plasma viremia becomes undetectable under HAART, virions can still be detected by in situ hybridization on lymph node FDCs.35,44 A better correlation between plasma and lymphoid organ viral load is found when plasma RNA detection thresholds are lower (< 20 copies/mL) than in the tests used here45 or when the frequency of infected cells in the lymphoid organs is measured.46 Here, the frequencies of HIV DNA+ cells in the lymphoid organs were 1 to 2 logs lower in the patients treated with HAART than in the other patients with detectable plasma viral loads. Therefore, HAART resulted in undetectable plasma viremia, a decrease in lymphoid organ viral load, and a disappearance of local cytotoxic activity. Similar conclusions on the disappearance of CTL activity have been made in peripheral blood.29,30,39,47-49 However, in lymph node germinal centers and in tonsils, increased numbers of CD8+ T cells were still found 3 months after viral replication was controlled in HIV-infected patients.35,50 Here CD8+ T cell infiltration was observed in the lymphoid organs from the 4 patients, but the effector function was no longer present when viral load, hence antigen production, was reduced by HAART. In peripheral blood, CTL activity disappears shortly after viral load (ie, HIV antigens) is reduced to undetectable levels by HAART30,39,47 and is absent in some long-term nonprogressors harboring defective virus51: Chronic antigen stimulation is necessary for sustained effector CTL activity. This is probably also true at the microanatomic level in the white pulps and germinal centers. In contrast to the activity usually observed after in vitro culture, the direct CTL activity in fresh individual white pulps or germinal centers represents in vivo clonally expanded activated CTLs responding to local HIV antigen production. Indeed, even if they were not systematically found in the same white pulps, CTL effectors and replicating virus were concentrated in these structures. Analysis of quasi species shows that HIV replicates locally in individual white pulps, but this replication is strongly limited19b (M. J. Dumaurier et al, unpublished data, June 2000). The data presented here confirm the major role of HIV-specific CTL effectors in this strong restriction of viral spread in vivo and can provide clues to target therapeutic intervention.
We thank Pr Jean-Pierre Clauvel and Jean-Gérard Guiller for support, Drs Valérie Pézo, Jean-François Desoutter, and Guislaine Carcelain for help, Dr Marie Paule Kieny from Transgene for vaccinia viruses, Dr Ioannis Theodorou and his team for HLA typing, Dr Pierre Langlade for w6/32 antibody, Drs Mireille Viguier and Marc Dalod for reading the manuscript, and Dr Rafick P. Sekaly for helpful discussion.
Submitted April 6, 2000; accepted December 10, 2000.
Supported by grants from the Institut Pasteur, the Agence Nationale de la Recherche contre le SIDA (ANRS), and Sidaction/Ensemble contre le SIDA (A.S.). M.J.D. was supported by an ANRS fellowship.
A.S. and M.-J.D. contributed equally to this work.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Anne Hosmalin, Unité INSERM 445, Institut Cochin de Génétique Moléculaire, Bâtiment Gustave Roussy, 27 rue du Faubourg St Jacques, 75014 Paris, France; e-mail: hosmalin{at}cochin.inserm.fr.
1. Cheynier R, Gratton S, Halloran M, Stahmer I, Letvin NL, Wain-Hobson S. Antigenic stimulation by BCG vaccine as an in vivo driving force for SIV replication and dissemination. Nat Med. 1998;4:421-427[CrossRef][Medline] [Order article via Infotrieve].
2.
Ostrowski M, Krakauer D, Li Y, et al.
Effect of immune activation on the dynamics of human immunodeficiency virus replication and on the distribution of viral quasispecies.
J Virol.
1998;72:7772-7784 3. Armstrong JA, Horne R. Follicular dendritic cells and virus-like particles in AIDS-related lymphadenopathy. Lancet. 1984;ii:370-372. 4. Biberfeld P, Chayt KJ, Marselle LM, Biberfeld G, Gallo RC, Harper ME. HTLV-III expression in infected lymph nodes and relevance to pathogenesis of lymphadenopathy. Am J Pathol. 1986;125:436-442[Abstract]. 5. Embretson J, Zupancic M, Ribas JL, et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature. 1993;362:359-362[CrossRef][Medline] [Order article via Infotrieve]. 6. LeTourneau A, Audouin J, Diebold J, Marche C, Tricottet V, Reynes M. LAV-like particles in lymph node germinal centers in patients with the persistent lymphadenopathy syndrome and the acquired immunodeficiency syndrome-related complex: an ultrastructural study of 30 cases. Hum Pathol. 1986;17:1047-1053[CrossRef][Medline] [Order article via Infotrieve]. 7. Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature. 1993;362:355-358[CrossRef][Medline] [Order article via Infotrieve]. 8. Tenner-Racz K, Racz P, Dietrich M, Kern P. Altered follicular dendritic cells and virus-like particles in AIDS and AIDS-related lymphadenopathy. Lancet. 1985;i:105-106. 9. Prevot S, Fournier J, Tardivel I, Audouin J, Diebold J. Detection by in situ hybridization of HIV-1 RNA in spleens of HIV-1 seropositive patients with thrombocytopenic purpura. Pathol Res Pract. 1989;185:187-193[Medline] [Order article via Infotrieve]. 10. Emilie D, Peuchmaur M, Maillott M, et al. Production of interleukins in HIV-1-replicating lymph nodes. J Clin Invest. 1990;86:148-159. 11. Fox CH, Tenner-Racz K, Racz P, Firpo A, Pizzo PA, Fauci AS. Lymphoid germinal centers are reservoirs of human immunodeficiency virus type 1 RNA. J Infect Dis. 1991;164:1051-1057[Medline] [Order article via Infotrieve]. 12. Hufert F, van Lunzen J, Janossy G, et al. Germinal centre CD4+ T cells are an important site of HIV replication in vivo. AIDS. 1997;11:849-857[CrossRef][Medline] [Order article via Infotrieve]. 13. McIlroy D, Autran B, Cheynier R, et al. Dendritic cell and CD4+ T lymphocyte infection frequency in spleens of HIV-positive patients. J Virol. 1995;69:4737-4745[Abstract]. 14. Spiegel H, Herbst H, Niedobitek G, Foss H-D, Stein H. Follicular dendritic cells are a major reservoir for human immunodeficiency virus type 1 in lymphoid tissues facilitating infection of CD4+ T-helper cells. Am J Pathol. 1992;140:15-22[Abstract]. 15. Schmitz J, van Lunzen J, Tenner-Racz K, et al. Follicular dendritic cells retain HIV-1 particles on their plasma membrane, but are not productively infected in asymptomatic patients with follicular hyperplasia. J Immunol. 1994;153:1352-1359[Abstract].
16.
Delassus S, Cheynier R, Wain-Hobson S.
Non-homogeneous distribution of human immunodeficiency virus type 1 proviruses in the spleen.
J Virol.
1992;66:5642-5645 17. Cheynier R, Henrichwark S, Hadida F, et al. HIV and T-cell expansion in splenic white pulps is accompanied by infiltration of HIV-specific cytotoxic T-lymphocytes. Cell. 1994;78:373-387[CrossRef][Medline] [Order article via Infotrieve]. 18. Plata F, Autran B, Martins LP, et al. AIDS virus-specific cytotoxic T lymphocytes in lung disorders. Nature. 1987;328:348-351[CrossRef][Medline] [Order article via Infotrieve]. 19a. Wong J, Ignacio C, Torriani F, Havlir D, Fitch N, Richman D. In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues. J Virol. 1997;71:2059-2071[Abstract].
19b.
Gratton S, Cheynier R, Dumaurier MJ, Oksenhendler E, Wain-Hobson S.
Highly restricted spread of HIV-1 and multiply infected cells within splenic germinal centers.
Proc Natl Acad Sci U S A.
2000;97:14566-14571
20.
Letvin NL.
Progress in the development of an HIV-1 vaccine.
Science.
1998;280:1875-1880
21.
Walker CM, Moody DJ, Stites DP, Levy JA.
CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication.
Science.
1986;234:1563-1566 22. Yang O, Walker B. CD8+ cells in human immunodeficiency virus type I pathogenesis: cytolytic and noncytolytic inhibition of viral replication. Adv Immunol. 1997;66:273-311[Medline] [Order article via Infotrieve].
23.
Koup RA, Safrit JT, Cao Y, et al.
Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.
J Virol.
1994;68:4650-4655
24.
Borrow P, Lewicki H, Hahn B, Shaw G, Oldstone M.
Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection.
J Virol.
1994;68:6103-6110
25.
Pantaleo G, Demarest JF, Soudeyns H, et al.
Major expansion of CD8+ T cells with a predominant V
26.
Kuroda M, Schmitz J, Charini W, et al.
Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys.
J Immunol.
1999;162:5127-5133 27. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996;272:1167-1170[Abstract]. 28. Rinaldo C, Huang X, Fan Z, et al. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J Virol. 1995;69:5838-5842[Abstract].
29.
Musey L, Hughes J, Schacker T, Shea T, Corey L, McElrath J.
Cytotoxic T cell responses, viral load and disease progression in early HIV-1 infection.
N Engl J Med.
1997;337:1267-1274
30.
Ogg G, Jin X, Bonhoeffer S, et al.
Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA.
Science.
1998;279:2103-2106
31.
Schmitz JE, Kuroda MJ, Santra S, et al.
Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes.
Science.
1999;283:857-860
32.
Jin X, Bauer D, Tuttleton S, et al.
Dramatic rise in plasma viremia after CD8+ T cell depletion in SIV-infected macaques.
J Exp Med.
1999;189:991-998
33.
Matano T, Shibata R, Siemon C, Connors M, Lane H, Martin M.
Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques.
J Virol.
1998;72:164-169 34. Racz P, Tenner-Racz K, van Vloten F, et al. Lymphatic tissue changes in AIDS and other retrovirus infections: tools and insights. Lymphology. 1990;23:85-91[Medline] [Order article via Infotrieve].
35.
Tenner-Racz K, Stellbrink HJ, van Lunzen J, et al.
The unenlarged lymph nodes of HIV-1 infected, asymptomatic patients with high CD4 T cell counts are sites for virus replication and CD4 T cell proliferation: the impact of highly active antiretroviral therapy.
J Exp Med.
1998;187:949-959 36. Hadida F, Parrot A, Kieny M-P, et al. Carboxy-terminal and central regions of human immunodeficiency virus-1 NEF recognized by cytotoxic T lymphocytes from lymphoid organs. J Clin Invest. 1992;89:53-60.
37.
Kuroda M, Schmitz J, Charini W, et al.
Comparative analysis of cytotoxic T lymphocytes in lymph nodes and peripheral blood of SIV-infected Rhesus monkeys.
J Virol.
1999;73:1573-1579 38. Brodie S, Lewinsohn D, Patterson B, et al. In vivo migration and function of transferred HIV-1 specific cytotoxic T cells. Nat Med. 1999;5:34-41[CrossRef][Medline] [Order article via Infotrieve].
39.
Gray C, Lawrence J, Schapiro J, et al.
Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART).
J Immunol.
1999;162:1780-1788
40.
Zajac A, Blattman J, Murali-Krishna K, et al.
Viral immune evasion due to persistence of activated T cells without effector function.
J Exp Med.
1998;188:2205-2213 41. Ehl S, Klenerman P, Aichele P, Hengartner H, Zinkernagel R. A functional and kinetic comparison of antiviral effector and memory CTL populations in vivo and in vitro. Eur J Immunol. 1997;27:3404-3413[Medline] [Order article via Infotrieve].
42.
Wong J, Gunthard H, Havlir D, et al.
Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure.
Proc Natl Acad Sci U S A.
1997;94:12574-12579 43. Lafeuillade A, Chollet L, Hittinger G, Profizi N, Costes O, Poggi C. Residual human immunodeficiency virus type 1 RNA in lymphoid tissue of patients with sustained plasma RNA of < 200 copies/mL. J Infect Dis. 1998;177:235-238[Medline] [Order article via Infotrieve].
44.
Zhang Z, Schuler T, Cavert W, et al.
Reversibility of the pathological changes in the follicular dendritic cell network with treatment of HIV infection.
Proc Natl Acad Sci U S A.
1999;96:5169-5172 45. Perrin L, Yerly S, Marchal F, et al. Virus burden in lymph nodes and blood of subjects with primary human immunodeficiency virus type 1 infection on bitherapy. J Infect Dis. 1998;177:1497-1501[CrossRef][Medline] [Order article via Infotrieve].
46.
Hockett R, Kilby J, Derdeyn C, et al.
Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA.
J Exp Med.
1999;189:1545-1554 47. Dalod M, Harzic M, Pellegrin I, et al. Evolution of CTL responses to HIV type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapy. J Infect Dis. 1998;178:61-69[Medline] [Order article via Infotrieve]. 48. Carcelain G, Blanc C, Leibowitch J, et al. T cell changes after combined nucleoside analogue therapy in HIV primary infection. AIDS. 1999;13:1077-1081[CrossRef][Medline] [Order article via Infotrieve].
49.
Kalams S, Goulder P, Shea A, et al.
Levels of HIV-1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia wih highly active antiretroviral therapy.
J Virol.
1999;73:6721-6728 50. Dyrhol-Riise A, Voltersvik P, Olofson J, Asjö B. Activation of CD8 T cells normalizes and correlates with the level of provirus in tonsils during highly active antiretroviral therapy in early HIV-1 infection. AIDS. 1999;13:2365-2376[CrossRef][Medline] [Order article via Infotrieve].
51.
Binley J, Jin X, Huang Y, et al.
Persistent antibody responses but declining CTL responses to multiple HIV type 1 antigens in a long term non progressing individual with a defective p17 proviral sequence and no detectable viral RNA expression.
J Virol.
1998;72:3472-3474
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  M. Nascimbeni, L. Perie, L. Chorro, S. Diocou, L. Kreitmann, S. Louis, L. Garderet, B. Fabiani, A. Berger, J. Schmitz, et al. Plasmacytoid dendritic cells accumulate in spleens from chronically HIV-infected patients but barely participate in interferon-{alpha} expression Blood, June 11, 2009; 113(24): 6112 - 6119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Connick, T. Mattila, J. M. Folkvord, R. Schlichtemeier, A. L. Meditz, M. G. Ray, M. D. McCarter, S. MaWhinney, A. Hage, C. White, et al. CTL Fail to Accumulate at Sites of HIV-1 Replication in Lymphoid Tissue J. Immunol., June 1, 2007; 178(11): 6975 - 6983. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-J. Dumaurier, S. Gratton, S. Wain-Hobson, and R. Cheynier The majority of human immunodeficiency virus type 1 particles present within splenic germinal centres are produced locally J. Gen. Virol., December 1, 2005; 86(12): 3369 - 3373. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Renoux, S. Wain-Hobson, B. Hurtrel, and R. Cheynier Antigenic Stimulation Specifically Reactivates the Replication of Archived Simian Immunodeficiency Virus Genomes in Chronically Infected Macaques J. Virol., September 1, 2005; 79(17): 11231 - 11238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Fagard, A. Oxenius, H. Gunthard, F. Garcia, M. Le Braz, G. Mestre, M. Battegay, H. Furrer, P. Vernazza, E. Bernasconi, et al. A Prospective Trial of Structured Treatment Interruptions in Human Immunodeficiency Virus Infection Arch Intern Med, May 26, 2003; 163(10): 1220 - 1226. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Andrieu, J.-F. Desoutter, E. Loing, J. Gaston, D. Hanau, J.-G. Guillet, and A. Hosmalin Two Human Immunodeficiency Virus Vaccinal Lipopeptides Follow Different Cross-Presentation Pathways in Human Dendritic Cells J. Virol., December 20, 2002; 77(2): 1564 - 1570. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Zhang, L. Rowe, T. He, C. Chung, J. Yu, W. Yu, A. Talal, M. Markowitz, and D. D. Ho Compartmentalization of Surface Envelope Glycoprotein of Human Immunodeficiency Virus Type 1 during Acute and Chronic Infection J. Virol., August 12, 2002; 76(18): 9465 - 9473. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Blancou, N. Chenciner, M.-C. Cumont, S. Wain-Hobson, B. Hurtrel, and R. Cheynier The infiltration kinetics of simian immunodeficiency virus-specific T cells drawn to sites of high antigenic stimulation determines local in vivo viral escape PNAS, October 25, 2001; (2001) 231348598. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Blancou, N. Chenciner, M.-C. Cumont, S. Wain-Hobson, B. Hurtrel, and R. Cheynier The infiltration kinetics of simian immunodeficiency virus-specific T cells drawn to sites of high antigenic stimulation determines local in vivo viral escape PNAS, November 6, 2001; 98(23): 13237 - 13242. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
made of T lymphocytes and dendritic cells
chain.
minimal
release)/(maximal release 
) or wild-type vaccinia (
). Results from 11 representative white pulps of the 24 tested and from bulk SMCs
are shown.
